Project Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 abiraterone abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy
Latest Posts
- Not All Patients Benefit Equally: New Score Refines Cabazitaxel Use April 25, 2026
- B7‑H3 Expression Shapes Prognosis Differently Across Prostate Cancer Stages April 24, 2026
- DNA Smart Drugs: Precision Cancer Treatment With a Double Lock April 22, 2026
- Double-Masked PSMA-TCE JANX014 Enters Phase 1 for mCRPC April 21, 2026
Another Potential Breakthrough: 3-in-1 Antibody Shows Promise
/in Immunotherapy, Not PCa related, Preclinical Research/by MaxApalutamide Shows Promising Survival Outcomes in Metastatic Castration-Sensitive Prostate Cancer: A Real-World Analysis
/in Observational, Post-hoc, Retrospective studies/by MaxAn add-on strategy to maximize workouts: electro stimulation works for cancer patients
/in Clinical Trial, Metastatic/by MaxHopefully a Breakthrough: CLSP-1025 Targets Common p53 Mutation, Paving New Path for Solid Tumor Immunotherapy
/in Immunotherapy, Not PCa related, Preclinical Research/by MaxUnlocking the Fortress: Good News for Immunotherapy Directed to Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1/by MaxAnother AlphaFold evolution: Using AI to Identify Better Antibody Therapies
/in Artificial Intelligence, Not PCa related/by MaxAlphaFold keeps rocking: a new AI tool that can predict large proteins
/in Artificial Intelligence/by MaxBreakthrough discovery (in vitro): selective MMP7 inhibitor for cancer treatment
/in Not PCa related, Preclinical Research/by Max